Kodiak Sciences (NASDAQ:KOD) Director Buys $2,868,396.30 in Stock

Posted by Geri Gentry on Sep 30th, 2026

Kodiak Sciences Inc. (NASDAQ:KOD – Get Free Report) Director Bros. Advisors Lp Baker bought 33,726 shares of the stock in a transaction dated Tuesday, September 29th. The stock was bought at an average cost of $85.05 per share, for a total transaction of $2,868,396.30. Following the acquisition, the director directly owned 20,191,214 shares of the company’s stock, valued at approximately $1,717,262,750.70. This represents a 0.17% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Bros. Advisors Lp Baker also recently made the following trade(s):

On Monday, September 28th, Bros. Advisors Lp Baker purchased 807,840 shares of Kodiak Sciences stock. The stock was bought at an average price of $72.57 per share, for a total transaction of $58,624,948.80.
On Monday, September 28th, Bros. Advisors Lp Baker acquired 418,323 shares of Kodiak Sciences stock. The shares were bought at an average cost of $83.58 per share, with a total value of $34,963,436.34.
On Monday, September 28th, Bros. Advisors Lp Baker bought 681,866 shares of Kodiak Sciences stock. The stock was purchased at an average cost of $88.77 per share, for a total transaction of $60,529,244.82.

Kodiak Sciences Stock Up 4.0%

Kodiak Sciences stock traded up $3.68 during midday trading on Wednesday, reaching $94.80. 4,897,441 shares of the stock traded hands, compared to its average volume of 1,094,203. The stock’s fifty day moving average is $40.26 and its 200-day moving average is $38.27. Kodiak Sciences Inc. has a 12 month low of $10.94 and a 12 month high of $98.80. The stock has a market cap of $5.96 billion, a P/E ratio of -22.63 and a beta of 2.18.

Kodiak Sciences (NASDAQ:KOD – Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.96) by ($0.09). On average, equities analysts predict that Kodiak Sciences Inc. will post -3.89 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

KOD has been the topic of a number of recent research reports. Lifesci Capital upped their price target on shares of Kodiak Sciences from $85.00 to $145.00 and gave the company an “outperform” rating in a research note on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Kodiak Sciences in a research note on Friday, July 10th. UBS Group boosted their target price on shares of Kodiak Sciences from $80.00 to $120.00 and gave the stock a “buy” rating in a report on Monday. Jefferies Financial Group restated a “buy” rating and set a $112.00 target price on shares of Kodiak Sciences in a research report on Monday. Finally, JPMorgan Chase & Co. increased their price target on shares of Kodiak Sciences from $56.00 to $66.00 and gave the company an “overweight” rating in a report on Monday, August 3rd. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $100.43.

Read Our Latest Research Report on Kodiak Sciences

Trending Headlines about Kodiak Sciences

Here are the key news stories impacting Kodiak Sciences this week:

Positive Sentiment: Kodiak said Zenkuda and tabirafusp-ted achieved the primary endpoints in the Phase 3 DAYBREAK study for wet age-related macular degeneration, reportedly matching Eylea on efficacy while supporting the potential benefits of longer-lasting eye treatments. The results are the main catalyst behind the stock’s sharp increase. KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears
Positive Sentiment: The company is advancing Zenkuda toward a Biologics License Application filing, strengthening expectations that Kodiak could move from a development-stage biotech toward a commercial product opportunity. Kodiak Sciences Inc. Advances Zenkuda Toward Filing
Positive Sentiment: HC Wainwright maintained a Buy rating and a $96 price target while raising its long-term EPS forecasts, including estimates of $1.76 for fiscal 2029 and $5.81 for fiscal 2030. It also improved its fiscal 2028 loss estimate, though its fiscal 2027 loss forecast worsened slightly. HC Wainwright Kodiak Sciences analyst estimates
Positive Sentiment: Additional analyst coverage from Lifesci Capital, UBS Group and HC Wainwright has pointed to higher valuation potential following the clinical update. Kodiak Sciences Stock Gets Price Target Boost from Lifesci Capital
Neutral Sentiment: Unusually high put-option buying indicates that some traders are hedging or positioning for a pullback after the sharp rally, but it does not by itself establish a fundamental change in the company’s outlook. Kodiak Sciences Stock Sees Unusually High Put Option Buying
Negative Sentiment: Despite the clinical success, Kodiak remains a cash-burning biotech with no revenue and ongoing development expenses. Analysts and commentators warn that a potential share offering could fund operations but dilute existing shareholders, making the stock’s sharp repricing difficult to chase. A $32 Biotech Became a $90 Biotech Overnight

Institutional Trading of Kodiak Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of KOD. BlackRock Inc. bought a new stake in Kodiak Sciences in the second quarter worth $161,113,000. Baker BROS. Advisors LP increased its position in Kodiak Sciences by 15.1% during the fourth quarter. Baker BROS. Advisors LP now owns 19,919,186 shares of the company’s stock valued at $556,940,000 after acquiring an additional 2,608,696 shares during the last quarter. Jupiter Topco LLC bought a new position in Kodiak Sciences during the second quarter valued at $59,507,000. ICONIQ Capital LLC purchased a new stake in shares of Kodiak Sciences in the second quarter valued at $49,345,000. Finally, Bank of America Corp DE purchased a new stake in shares of Kodiak Sciences in the second quarter valued at $14,949,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

About Kodiak Sciences

(Get Free Report)

Kodiak Sciences Inc (NASDAQ: KOD) is a biopharmaceutical company focused on developing therapies for retinal diseases and other conditions affecting the eye. The company’s research is centered on antibody biopolymer conjugates, a technology designed to extend the duration of action of biologic medicines in ocular tissues and potentially reduce the frequency of administration.

Its lead development program has been tarcocimab tedromer, also known as KSI-301, an anti-vascular endothelial growth factor (VEGF) therapy investigated for retinal vascular diseases, including diabetic macular edema, diabetic retinopathy and neovascular age-related macular degeneration.